* Oscar Health Inc OSCR.N OSCR.K is expected to show a
rise in
quarterly revenue when it reports results on May 7 for the
period ending March 31 2024
* The New York City-based company is expected to report a
36.8% increase in revenue to $2.011 billion from $1.47 billion a
year ago, according to the mean estimate from 3 analysts, based
on LSEG data.
* LSEG's mean analyst estimate for Oscar Health Inc is for
earnings of 27 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Oscar
Health Inc
is $19.50, above its last closing price of $18.09.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.73 -0.72 -0.66 Beat 8.7
Sep. 30 2023 -0.47 -0.47 -0.29 Beat 38.6
Jun. 30 2023 -0.22 -0.23 -0.07 Beat 69.6
Mar. 31 2023 -0.04 -0.05 -0.18 Missed -254.7
Dec. -1.09 -1.16 -1.05 Beat 9.5
31 2022
Sep. 30 2022 -0.72 -0.73 -0.91 Missed -24.6
Jun. 30 2022 -0.51 -0.48 -0.53 Missed -10.8
Mar. 31 2022 -0.21 -0.21 -0.36 Missed -68.6
This summary was machine generated May 3 at 14:59 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)